Cognition Therapeutics, Inc. is a clinical-stage neuroscience company developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders.
The company’s technology “selectively modulates” a central cellular damage response pathway, allowing the body to heal itself. It believes its technology could be a huge leap forward in combating these debilitating diseases.
